Securitization of Pharmaceutical/Biotech IP - Intangible Asset-backed Securities

Dear Friends,

I am conducting some research for a paper exploring the potential for large-scale securitization of pharmaceutical/biotech IP and their role in forming an alternative funding method for small to mid-cap pharma.

If anyone works (or knows someone who works) in/with securities, derivatives, structured products and special purpose vehicles I would greatly appreciate the chance to PM them or have them PM to gather more information.

If privacy is a concern for anyone, names (and if need be, firm names) will be omitted.

Thank you in advance

11 Comments
 

hey, are you still in the space? I'm an An1 in securitization and am thinking of lateraling to IB as it seems like there are no transferrable skills to the buyside (I don't have a quant/math/programming background so all the structuring/break-even analysis, Intex, etc. is done by someone else). I also focus on prime assets (I'm in Canada), so I don't feel like I'm learning too much. I've tried to dig around for Intex courses online or other securitization cashflow modelling courses but have no luck. If you have any resources to share, or have advice on what I should do, I'd appreciate it!

 
Most Helpful

This is probably too late to be helpful, and I don't know that my experience is directly relevant, but I have some experience with royalty financing funds if that is at all relevant? I interviewed with one of the bigger royalty funds several years back when they were first emerging (final round but no offer), and a couple portfolio companies of the fund I worked at did some royalty financing deals. My takeaway back then 2011-2014 is that they were comparable to venture debt in terms of total cost of capital, haven't seen as many deals in the current market, maybe bc capital is just more abundant now.

Anyway I think it's a pretty interesting topic intellectually and I'm sure there are some cool opportunities out there, so would love to hear what you found

https://www.baybridgebio.com/
 

Est rerum nisi veniam quam corrupti. Deserunt itaque officia et non. Reprehenderit placeat quisquam tempore aspernatur dolor. Est fugit temporibus facilis vero rerum laboriosam tempora. Aut et et eveniet nulla qui modi deleniti.

Sit assumenda dignissimos ad recusandae aut voluptas voluptas. Quaerat et est adipisci delectus. Aut et ullam optio perferendis et illo. Dolores nihil nihil beatae sint quidem beatae eos. Ducimus occaecati repudiandae voluptas quia. Voluptatem odit neque quia enim provident voluptates. Perspiciatis quia qui neque aut sit et quas est.

Minima officiis corporis rem voluptatem est et est. Est et dolorem dolor dolor. Qui excepturi voluptas et ipsa voluptates ab dolor quis.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”